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 ABSTRACT 
 Objective  To determine the safety of ciprofl oxacin in 
paediatric patients in relation to arthropathy, any other 
adverse events (AEs) and drug interactions. 
 Methods  A systematic search of MEDLINE, EMBASE, 
CINAHL, CENTRAL and bibliographies of relevant articles 
was carried out for all published articles, regardless 
of design, that involved the use of ciprofl oxacin in any 
paediatric age group ≤17 years. Only articles that 
reported on safety were included. 
 Results  105 articles met the inclusion criteria and 
involved 16 184 paediatric patients. There were 1065 
reported AEs (risk 7%, 95% CI 3.2% to 14.0%). The 
most frequent AEs were musculoskeletal AEs, abnormal 
liver function tests, nausea, changes in white blood cell 
counts and vomiting. There were six drug interactions 
(with aminophylline (4) and methotrexate (2)). The 
only drug related death occurred in a neonate who had 
an anaphylactic reaction. 258 musculoskeletal events 
occurred in 232 paediatric patients (risk 1.6%, 95% CI 
0.9% to 2.6%). Arthralgia accounted for 50% of these. 
The age of occurrence of arthropathy ranged from 
7 months to 17 years (median 10 years). All cases of 
arthropathy resolved or improved with management. 
One prospective controlled study estimated the risk of 
arthropathy as 9.3 (OR 95% CI 1.2 to 195). Pooled safety 
data of controlled trials in this review estimated the risk 
of arthropathy as 1.57 (OR 95% CI 1.26 to 1.97). 
 Conclusion  Musculoskeletal AEs occur due to 
ciprofl oxacin use. However, these musculoskeletal events 
are reversible with management. It is recommended that 
further prospective controlled studies should be carried 
out to evaluate the safety of ciprofl oxacin, with particular 
focus on the risk of arthropathy. 
 INTRODUCTION 
 The fi rst quinolone discovered was nalidixic acid 
in 1962, as a by-product of antimalarial research. 
Its use was limited due to its narrow spectrum of 
antibacterial activity, low serum levels and toxic-
ity issues. 1 Fluorination of the quinolone nucleus 
at position 6 resulted in introduction of second, 
third and fourth generations of fl uoroquinolones, 
with ciprofl oxacin in 1987 as a second generation 
fl uoroquinolone. 2 Ciprofl oxacin is a broad spec-
trum, bactericidal antibiotic which acts by bind-
ing two of the four topoisomerases of bacteria. 3 
 The use of ciprofl oxacin and fl uoroquinolones as 
a group in paediatric patients has been limited due 
to arthropathy noticed in weight bearing joints 
of juvenile animals. Cartilage damage caused 
by quinolones (nalidixic, oxolinic and pipemidic 
acids) was fi rst reported in juvenile animals (bea-
gle dogs 4–12 months of age). 4 The arthropathy 
caused by quinolones has also been demonstrated 
in other animal species such as mice, 5 dogs, 6 rats 7 
and  rabbits, 8 and in in-vitro animal culture 9 and 
in-vitro human cell culture. 10 
 Due to the good antibacterial activity and tissue 
penetration, different investigators have used cip-
rofl oxacin in paediatric patients. The occurrence 
of arthropathy is uncertain. Other adverse drug 
reactions and drug interactions have been reported 
with ciprofl oxacin use in adults. 11 However, the 
drug toxicity profi le has not been ascertained in 
paediatric use. This systematic review aims to 
pool together all the safety data about use of cip-
rofl oxacin in paediatrics, with a critical look at the 
occurrence of arthropathy. 
 METHODS 
 Search strategy 
 We searched MEDLINE (1950 to November 2009), 
EMBASE (1950 to November 2009), the Cochrane 
database for systematic reviews, the Cochrane 
Central Register of Controlled Trials (CENTRAL), 
and the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL) for any study with 
documented involvement of any paediatric age 
group (0–17 years) that used ciprofl oxacin as 
intervention via any route of administration and 
for any disease condition. There was no restric-
tion on the type of study that was included, lan-
guage of publication or inclusion of abstracts. 
Any study with involvement of a paediatric age 
group participant taking at least a single dose of 
ciprofl oxacin was included. This was necessary to 
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 What is already known on this topic 
 Ciprofl oxacin is a broad spectrum, bactericidal  ▶
antibiotic with good tissue penetration. 
 Ciprofl oxacin and fl uoroquinolones as a group,  ▶
cause arthropathy in weight bearing joints of 
juvenile animals. 
 The use of ciprofl oxacin in paediatrics has been  ▶
limited due to the possibility of arthropathy. 
 What this study adds 
 Musculoskeletal adverse events (AEs) are the  ▶
most frequently reported AEs in paediatric 
patients after ciprofl oxacin use. 
 All musculoskeletal AEs reported in the  ▶
literature have been reversible following 
withdrawal of ciprofl oxacin. 
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ascertain the extent of use of ciprofl oxacin in paediatrics and 
to be able to pool any documented adverse events (AEs) involv-
ing any paediatric age group. Hand searching of references of 
articles was also done. Studies that involved only adults were 
excluded. Search terms comprised both subject headings and 
free text words. These included terms relating to ciprofl oxacin 
or quinolones or fl uoroquinolones; adverse effects or adverse 
drug reactions or side effects; arthropathy or cartilage toxicity 
or chondrotoxicity or joint damage; and pharmacokinetics (see 
online supplementary appendix 1 ). 
 Outcome measures 
 The prespecifi ed outcomes were as follows: 
Occurrence of arthropathy specifi ed as joint pain, joint 1. 
swelling, reduced movement of joint or radiographic evi-
dence of joint damage and any other musculoskeletal AE. 
 Occurrence of any other AEs from ciprofl oxacin use. 2. 
 Occurrence of drug–drug interactions due to ciprofl oxacin 3. 
use. 
 Death due to adverse drug reaction from ciprofl oxacin 4. 
use. 
 Data collection and analysis 
 The relevant data were extracted onto the data extraction 
form. Only studies that reported on the number of paediatric 
patients within each study and reported on safety of cipro-
fl oxacin in the paediatric patients were analysed. Participants 
in the study were grouped into the following paediatric age 
groups: preterm neonates (<36 weeks gestation, 0–27 days); 
full-term neonates (0–27 days, >37 weeks gestation); infants 
and toddlers (28 days to 23 months); children (2–11 years); 
and adolescents (12–17 years). AEs were classifi ed accord-
ing to the WHO adverse reaction terminology classifi ca-
tion into one of the several organ systems, and were further 
analysed to determine which AEs actually occurred in any of 
the paediatric age groups (see online supplementary appen-
dix 2). The arthropathy reports were analysed for causality 
in relation to the time of exposure to the drug, presence of 
other disease and medications. 12 Details of the arthropathy 
included the time to development of arthropathy following 
ciprofl oxacin use; the time to follow-up of patients after use 
of ciprofl oxacin; method of detecting arthropathy in patients; 
and any management of the arthropathy. A  descriptive anal-
ysis of extracted data was performed. Statistical analysis was 
carried out using SPSS V.18 and GraphPad software. 
 RESULTS 
 We identifi ed a total of 105 studies ( fi gure 1 ), the majority of 
which were case series or case reports 13 – 117 ( table 1 ). However, 
most of the patients (88%) were within case series or cohort 
studies. 
 Dosage and formulations 
 The dose ranged from 3.1 to 93.8 mg/kg/day (oral) and 3.2 
to 76.9 mg/kg/day (intravenous). 68 The usual dose in at least 
60% of studies was 10–30 mg/kg/day in two divided doses 
for both oral and intravenous administration. The duration of 
ciprofl oxacin ranged from single dose (pharmacokinetic stud-
ies, therapy for cholera and prophylaxis for meningococcal 
disease) to 880 days (a 12-year-old with osteomyelitis). 68 The 
median duration of use was 14 days. 
 Due to the lack of a commercially available paediatric for-
mulation, various formulations were used, including a pre-
pared suspension from granular ciprofl oxacin, 16  18  66 tablets, 19 
 25  44  81  98  115 ground tablets, 82 a suspension formulation from 
Bayer, 13  22 pulverised tablets with sweet liquid, 42 and tablets 
crushed and mixed in cherry syrup. 70 Topical ciprofl oxacin 
was administered as drops to the eyes/ears. 
 Analysis of safety 
 All reported AEs were analysed together ( table 2 ). Sixty-eight 
studies reported AEs, while 37 studies reported no AEs. In 
total, 16 184 paediatric patients were exposed to ciprofl oxacin 
and there were 1065 reported AEs. This gave an estimated risk 
of 7 AEs in every 100 patients (7%, 95% CI 3.2% to 14.0%), or 
1 AE in every 14 patients receiving ciprofl oxacin. 
 The most frequent AEs were musculoskeletal problems, 
abnormal liver function tests, nausea, changes in white blood 
cell counts and vomiting ( table 2 ). These are pooled safety data 
of reported AEs by individual authors of the studies in our 
review. There was no dose dependent or duration dependent 
risk of toxicity. 
 Figure 1  Algorithm of the analysis of the studies in the systematic review. 
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 Drug related death occurred in a neonate who experienced 
an anaphylactic reaction following intravenous ciprofl oxacin. 
An additional 23 paediatric patients had to discontinue cipro-
fl oxacin due to serious AEs ( table 3 ). 
 There were six drug interactions with ciprofl oxacin. Four 
patients had drug interactions with aminophylline 47 (two 
patients were irritable/restless, one had tremors and one 
had hot fl ushes). Two patients had delayed elimination of 
 methotrexate. 55 However, there was no drug interaction with 
aminophylline in seven preterm babies. 21 
 Arthropathy 
 Thirty-two studies reported arthropathy, while 73 studies 
reported no arthropathy (37 studies reporting no AEs + 36 
studies of those reporting AEs that reported no arthropathy). 
There was no evidence that dose or duration had an effect on 
arthropathy. 
 In total, 16 184 paediatric patients were exposed to cipro-
fl oxacin; 258 musculoskeletal events occurred in 232 paediat-
ric patients (some patients had more than one musculoskeletal 
AE). This gave an estimated risk of 16 musculoskeletal AEs per 
1000 patients receiving ciprofl oxacin (1.6%, 95% CI 0.9% to 
2.6%) or one musculoskeletal AE in every 62.5 patients. A sum-
mary of the reported symptoms and/or signs of arthropathy is 
presented in  table 4 . Only 10 of the 32 studies gave detailed 
information regarding time and onset, duration of follow-up, 
method of detecting arthropathy and management. 
 The youngest documented case of arthropathy was in a 
7-month-old infant. 60 Age of occurrence was documented in 
47 paediatric patients; median age was 10 years. The time 
to follow-up of the patients after use of ciprofl oxacin was 
1 week to 50 months. 80  109 Of 47 studies reporting the time 
to follow-up of the patients, 31 studies (66%) followed up for 
an average time of ≥90 days. The time to development of any 
form of arthropathy was reported in 12 studies and ranged 
from 15 min to 30 days (median 6 days). 73  81 There were three 
additional cases of arthralgia that occurred on the fi rst day of 
treatment. 16  101 Management included continuation of drug 
use, discontinuation of drug with/without rechallenge, use of 
analgesics to relieve arthralgia, dose reduction or a combina-
tion of any of these measures. All cases of arthropathy with 
report on management resolved or improved. However, there 
was a report of arthralgia remaining unchanged in 1 out of 
31 reported arthralgia cases in a study. However, we are not 
certain if any management was instituted or for how long the 
arthralgia persisted. 74 
 Arthralgia accounted for 130 (50%) events. Four patients dis-
continued therapy due to arthralgia, which resolved in three 
patients (no report of the outcome in the last patient). 47  68 
Radiological confi rmation of arthropathy using MR1 was 
positive in two studies involving six cystic fi brosis patients, 
who had joint effusions, abnormal thickness of articular 
cartilage, non-homogeneous structure of cartilage or altered 
two-layer appearance of cartilage. 79  91 In addition to clinical 
examination and radiological investigation, seven studies (531 
cases and 674 controls) investigated the effects of ciprofl oxa-
cin on growth of patients after following up the patients for 
6–50 months. 28  32  33  63  75  109  116 None of these studies found 
 Table 1  Summary of 105 studies that reported on safety of 
ciprofl oxacin in paediatrics 
 Type of study  Frequency (N=105) 
 Number of patients 
(N=16 184) 
Case series 46 8876
Case report 24 24
RCT 15 1787
Cohort study 12 5368
Pharmacokinetic 5 79
Non-RCT 3 50
 Route of administration  Frequency (N=105)  Number of patients 
(N=16 184) 
Oral 39 1871
Intravenous 25 329
Intravenous and oral 19 6489
Not reported 16 6905
Topical 6 590
 Age group  Frequency (N) *  Number of patients † 
Children 67 NA
Adolescents 53 NA
Infants 40 NA
Preterm neonates 19 NA
Neonates (GA not stated) 18 NA
Term Neonates 9 NA
 * Total number of studies for age group is not 105 studies because multiple age 
groups were included within some studies. 
 † The number of patients in each age group could not be ascertained because most 
studies involved more than one age group and the number within each age group 
was not reported. 
 GA, gestational age; NA, not available; RCT, randomised controlled trial. 
 Table 2  Summary of reported adverse events (AEs) from 68 studies 
 AEs  Frequency 
Musculoskeletal 232 * 
Abnormal liver function tests 139
Nausea 75
Blood cell count derangements 57
Vomiting 56
Rash 51
Injection site reaction 47
Headache 41
Hearing/eye associated AEs 42
Abdominal pain/discomfort 38
Diarrhoea 36
Psychiatric disorders 18
Dizziness/decreased consciousness 13
Pruritus 2
Irritability/anxiety/nervousness 12
Photosensitivity 10
Acute renal failure/impaired renal function 9
Abdominal distension 8
Allergy/anaphylactoid reaction 7
Oral cavity abnormalities 6
Bleeding 6
Hemiparesis/hypotonia/hyperrefl exia/ataxia 5
Fever/hot fl ushes 5
Rigors/shivering/tremors 4
Interstitial nephritis 4
Others † 34
Not specifi ed ‡ 98
Total 1065
 * 232 patients had 258 musculoskeletal events. 
 † Others include AEs which occurred once, twice or thrice only. These include sei-
zures, haemolytic uraemic syndrome, pseudomembranous colitis, gastro-oesoph-
ageal refl ux disease, urinary retention, greenish discolouration of teeth, malaise, 
weight loss, dysuria, heart failure, sinoatrial nodal arrest and tachycardia. 
 ‡ Not specifi ed AEs reported as unknown. 
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any signifi cant difference in growth of the ciprofl oxacin 
exposed patients compared with the control arm. 
 The majority of the musculoskeletal events (223, 86%) were 
classifi ed as possibly related to ciprofl oxacin. Rechallenge 
with ciprofl oxacin was done in eight patients, but was positive 
in only a 9-year-old cystic fi brosis patient who had received 
17 mg/kg/day for 15 days and noticed arthralgia of elbow and 
knees on the sixth day post-therapy. 83  91  101 No information 
was given about how long arthralgia lasted on rechallenge and 
if any management was instituted. 
 Controlled studies 
 Only two studies estimated the risk of development of 
arthropathy in paediatric patients receiving ciprofl oxacin com-
pared to a control group. A prospective cohort study of 264 
cases and 249 controls matched for age and presence of cystic 
fi brosis, followed up patients for 15 days after the last dose of 
treatment. 101 An estimated crude OR for musculoskeletal AEs 
in the fl uoroquinolone group (ciprofl oxacin, ofl oxacin and per-
fl oxacin) compared to other antibiotics was 9.3 (95% CI 1.2 to 
195, p=0.02). Considering cystic fi brosis patients alone within 
the same study (approximately 90 patients in each group), the 
OR for musculoskeletal AEs in the fl uoroquinolone group com-
pared to other antibiotics was 1.2 (95% CI 0.1 to 35, p=0.99). 
The ORs estimated were not adjusted for possible infl uence of 
age and sex. 
 Second, a retrospective cohort study using a pharmacy 
 database of patients exposed to fl uoroquinolones and azithro-
mycin, checked for potential joint or tendon disorder diagnosed 
within 60 days of exposure to drug. 103 The joint or tendon dis-
orders were verifi ed from medical records of the patients by 
three blinded specialists. The study had over 4500 patients 
receiving ciprofl oxacin and over 1500 patients receiving ofl ox-
acin compared to over 15 000 patients receiving azithromycin. 
The estimated RR for verifi ed tendon or joint disorder for cip-
rofl oxacin was 1.04 (95% CI 0.72 to 1.51) and for ofl oxacin was 
1.04 (95% CI 0.55 to 1.84). The age and sex adjusted RR were 
1.08 (95% CI 0.74 to 1.58) for ciprofl oxacin and 1.13 (95% CI 
0.63 to 2.03) for ofl oxacin. 
 Safety data of all randomised controlled trials, non-ran-
domised controlled trials and cohort studies in our review 
were pooled together. Analysis of 23 controlled studies (7 con-
trolled studies were excluded because ciprofl oxacin or another 
fl uoroquinolone was administered in the comparator arm) 
comprising 6481 cases and 17 441 controls showed that there 
is a 57% increased risk of arthropathy in patients who received 
ciprofl oxacin compared to the comparator arm (OR 1.57, 95% 
CI 1.26 to 1.97). 13  15 – 19  28 – 33  63  75  76  79  101  103  105  109  111  112  116 
Further analysis of fi ve controlled studies that included only 
cystic fi brosis patients (227 cases and 391 controls) estimated 
a 67% increased risk of arthropathy (OR 1.67, 95% CI 1.13 to 
2.45). 17  19  79  101  105 
 DISCUSSION 
 Our systematic review about the safety of ciprofl oxacin is the 
fi rst review that has pooled together all reported suspected AEs 
due to ciprofl oxacin use in paediatric patients. Ciprofl oxacin is 
contraindicated in paediatrics because juvenile animals devel-
oped arthropathy after use. 4 However, our review has identi-
fi ed over 16 000 children who have received ciprofl oxacin. It 
is likely that the number of children who have received cipro-
fl oxacin in practice is signifi cantly greater than this. 
 Our review confi rms that musculoskeletal toxicity is the 
most frequently reported AE following the use of ciprofl oxa-
cin. There is, however, a wide range of toxicity that has been 
reported and it is important to recognise that, like all anti-
infective agents, ciprofl oxacin can be associated with a broad 
spectrum of AEs. The toxicity profi le in  table 2 is pooled safety 
data of reported suspected AEs by individual authors; how-
ever, these AEs may not be adverse drug reactions in all cases. 
From our review, there is an estimated risk of one musculosk-
eletal AE in every 62.5 patients, and a 57% increased risk of 
arthropathy in patients exposed to ciprofl oxacin. The muscu-
loskeletal AEs appear reversible with management. 
 The term arthropathy has been used broadly for various 
musculoskeletal AEs. Juvenile animals were noted to have 
gait stiffness, particularly in the hind limbs; reluctance to rise 
from a sitting, lateral or sternal recumbence position; exuda-
tion of synovial fl uid; and blistering and ulcerative erosions of 
articular cartilage in the limb joints. 4  118 However, our review 
suggested that arthralgia was the commonest symptom of 
arthropathy (50%) in paediatric patients, affecting mostly 
the knee joint. Tendon or joint disorders and reduced move-
ment also accounted for a signifi cant proportion of arthropa-
thy cases (19% and 15%, respectively). Although the specifi c 
tendon disorder could not be ascertained, tendinitis or tendon 
rupture could be implied as this represents the most frequent 
presentations in the literature. 119 – 121 The only specifi c report of 
tendon disorder in our review was a case of Achilles tendinitis 
in a patient (age not specifi ed). 106 Tendon disorders have been 
 Table 3  Summary of serious adverse events necessitating 
withdrawal and/or discontinuation of therapy 
 AE 
 Number of 
patients (n=23) 
Rash 5
Arthralgia 4
Vomiting and diarrhoea 2
Allergy 2
Anaphylactoid reaction 2
Epistaxis 1
Angioneurotic oedema 1
Cardiac failure 1
Sinus nodal arrest 1
Toxic megacolon 1
Nausea 1
Interstitial nephritis 1
Benign intracranial hypertension 1
 Table 4  Summary of reported musculoskeletal events from 32 
studies 
 Musculoskeletal events  Frequency (%) 
Arthralgia 130 (50.0)
Tendon or joint disorder 48 (19.0)
Reduced movement/stiffness 39 (15.0)
Joint swelling 8 (3.0)
Radiological confi rmed arthropathy 6 (2.3)
Myalgia 4 (1.6)
Arthritis 3 (1.2)
Pain in extremity 1 (0.4)
Osteitis 1 (0.4)
Unknown 18 (7.0)
Total 258 * (100)
 * 258 musculoskeletal events occurred in 232 patients. 
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thought to occur more frequently in patients over 60 years. 122 
However, our review suggests it is also reported in paediatric 
patients, and clinicians should be aware of such possibility. 
 Various molecular mechanisms have been postulated for 
arthropathy, such as inhibition of synthesis of collagen and 
glycosaminoglycans, inhibition in mitochondrial function 
resulting in generation of free radicals and oxidative stress or 
chelation of magnesium ions, all culminating in cartilage and 
tendon damage. 5  123 
 There appear to be differences in features of arthropathy in 
animals compared to humans. Two studies reported on the 
histopathology of the articular cartilage of three patients at 
postmortem examination, but no arthropathic lesions were 
noted. 64  91 However, animal studies showed exudation of 
synovial fl uid, blistering and ulcerative erosion of articu-
lar cartilage at postmortem examination, even after clinical 
recovery. 4 
 Animal studies have suggested that arthropathy occurs 
earlier in younger animals. 118 However, our review showed a 
median age of 10 years (range 7 months to 17 years) among 
47 age documented paediatric patients. Although most of the 
studies included in our review involved children (2–11 years), at 
least 389 neonates were exposed, with none developing mus-
culoskeletal AEs. The differences in growth between animals 
and humans have been suggested as a possible explanation for 
such differences. The number, location and time of appearance 
of secondary ossifi cation centres vary between animal species 
and humans. 
 Arthropathy in animals appears to be dose related, with 
increased risk in higher doses and after longer duration of 
treatment. 124  125 However, our data does not point to any dose 
dependent or duration dependent relationship in humans. 
 In conclusion, our review identifi ed only one prospective 
cohort study showing an increased risk of arthropathy, and we 
estimated an increased risk in those exposed to ciprofl oxacin. 
The concern of arthropathy in paediatric patients, based on 
studies in juvenile animals is therefore appropriate; however, 
the risk of arthropathy is relatively low and reversible with 
management. The risk of ciprofl oxacin-induced arthropathy 
needs to be considered in relation to the benefi ts of using cip-
rofl oxacin in children with acute infections. The role of cipro-
fl oxacin in paediatric and neonatal sepsis can only be clarifi ed 
by further prospective studies evaluating both the benefi t 
and the risk of toxicity, with a particular focus on the risk of 
arthropathy. 
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